Bone Biologics Announces Major United States Patent Issuances for Its Recombinant Protein Process.Bone Biologics, Inc. (Thousand Oaks, CA) announced that it has received a United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property Notice of Allowance of patent claims which protect a method of production for the UCB-1 (NELL-1) recombinant protein that Bone Biologics uses in the bone repair/regeneration technology in its lead product. Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX . The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX DBX Data Bus Accelerator DBX Debugger for Unix DBX Digital Private Branch Exchange DBX Data Base Extension DBX Dolby Stereo DBX Debugging Tools DBX Digital Branch Exchange DBX Extended Debugger DBX Data Byte X demineralized bone matrix to promote bone growth in spinal fusion. The platform technology will be subject to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review and approval process, including clinical trials. It is not currently approved for use in humans. The patent broadly protects the manufacturing method for the UCB-1 (NELL-1) protein. The UCB-1 (NELL-1) protein is currently utilized with a carrier (scaffold) of DBX demineralized bone matrix which is produced by the Musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles. mus·cu·lo·skel·e·tal adj. Relating to or involving the muscles and the skeleton. Transplant Foundation (MTF (1) (Modulation Transfer Function) A measurement of monitor sharpness. MTF compares the contrast ratio between alternating black and green lines that are one pixel thick. ). "The MTF is a world leader in tissue research and development, and has been both a financial and strategic partner to Bone Biologics over the past four years," noted Bruce A. Hazuka, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bone Biologics. "We are very pleased with the progress that Bone Biologics has made in achieving each of their development milestones over the past four years and look forward to their continued progress toward FDA approval and commercialization on the timelines projected by the company," Bruce Stroever, CEO of MTF said. MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2008, MTF distributed over 400,000 tissue grafts. Bone Biologics is a convergence biotechnology company focused in the orthobiologics space. The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years. The acquisition of an exclusive worldwide license and the financing from MTF was the genesis of the development of this recombinant protein. Bone Biologics, Inc. +1-818-324-2742 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion